PressNovember 28, 2022 Field Trip Health & Wellness Ltd. Announces Updated Time for Fiscal Second Quarter 2023 Financial Results and Conference Call
PressNovember 27, 2022 Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
PressNovember 27, 2022 Clearmind Announces Initiation of CMND-100 Manufacturing Program to Address its Upcoming Clinical Trial
PressNovember 27, 2022 Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
PressNovember 22, 2022 Field Trip Health & Wellness Ltd. Strengthens Leadership Team With Two Executive Appointments, Schedules Fiscal Second Quarter 2023 Conference Call
PressNovember 22, 2022 KAYA HOLDINGS, INC. Management’s Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)
PressNovember 22, 2022 Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, December 8, 2022
PressNovember 22, 2022 Nirvana Life Sciences Inc. announces agreement to acquire the licensed distributor of a Patented, WHO approved, herbal treatment for opiate addiction
PressNovember 21, 2022 Core One Labs Prepares for Commercial Production of API-Grade Psilocybin Plans Initial Production Run at GMP Facility in January
PressNovember 21, 2022 Mydecine Innovations Group Files Prospectus Supplement and Announces Closing Under Share Subscription Agreement
PressNovember 21, 2022 Wellbeing Subsidiary KGK Science Enters into Research Contract With Nova Mentis for Phase II A Clinical Trial
PressNovember 18, 2022 atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
PressNovember 18, 2022 Silo Wellness Wins Amendment to Proposed Land Use Ordinance for Oregon Psychedelic Ranch; Corporate Update: Shareholder FAQs
PressNovember 18, 2022 Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
PressNovember 18, 2022 Nova Mentis Enters into Research Contract with KGK Science for Phase II A Clinical Trial
BlogNovember 18, 2022 Neil Markey, CEO of Beckley Retreats, Sits in the Investor Hotseat on November 23rd
